Acute Bacterial Skin and Skin Structure Infections Market to Grow Substantially by 2032, Assesses DelveInsight | Key Companies - Melinta, AbbVie, Basilea, Motif Bio, Cubist, Paratek, Durata, The Medicine Company
23 août 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Market to Grow Substantially by 2032, Assesses DelveInsight | Key Companies - Melinta, AbbVie,...
Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies
24 mai 2021 20h30 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, May 24, 2021 (GLOBE NEWSWIRE) -- Acute Bacterial Skin and Skin Structure Infections Pipeline Featuring Plethora of Emerging Drugs, Key Companies Ceftobiprole Medocaril under...
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
08 mars 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics’ Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for Delafloxacin in Argentina
20 févr. 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Launches Antibiotic Baxdela™ (delafloxacin) in the United States
29 janv. 2018 07h00 HE
|
Melinta Therapeutics
– Approved for adult patients with acute bacterial skin and skin structure infections (ABSSSI) – – Provides coverage of gram-positive and gram-negative pathogens; only FDA-approved fluoroquinolone...
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
30 oct. 2017 08h01 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
04 oct. 2017 13h13 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
19 juin 2017 16h30 HE
|
Melinta Therapeutics
- Baxdela offers a new option for treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) including hospital-treated skin infections in oral and IV formulations as...
Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
28 févr. 2017 06h45 HE
|
Cempra, Inc.
—Management to host webcast and conference call today at 8:45 a.m. ET— CHAPEL HILL, N.C., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company...
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
24 févr. 2017 07h00 HE
|
Cempra, Inc.
—Fusidic acid met primary endpoint and secondary efficacy endpoints— —Fusidic acid well tolerated in the study— CHAPEL HILL, N.C., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a...